0 penilaian0% menganggap dokumen ini bermanfaat (0 suara)
13 tayangan9 halaman
CYP450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of the enzymes. When two agents that are substrates or inducer of the enzyme are administered together, drug interactions with significant clinical consequences may occur.
CYP450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of the enzymes. When two agents that are substrates or inducer of the enzyme are administered together, drug interactions with significant clinical consequences may occur.
CYP450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of the enzymes. When two agents that are substrates or inducer of the enzyme are administered together, drug interactions with significant clinical consequences may occur.
Judy W. M. Cheng, PharmD, MPH, FCCP, BCPS, 1 William H. Frishman, MD, 2 and Wilbert S. Aronow, MD 2 * Cytochrome P (CYP) 450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of CYP450 enzymes. When two agents that are substrates, inhibitors, or inducers of CYP450 are administered together, drug interactions with signicant clinical consequences may occur. This review discusses CYP450- mediated cardiovascular drug interactions as well as noncardiovascular drug interactions that produced signicant cardiovascular side effects. The principles in predicting drug interactions are also discussed. Keywords: Cytochrome P 450, drug interactions, cardiovascular drugs INTRODUCTION Cytochrome P (CYP) 450 is a superfamily of hemo- proteins found in human liver and other tissues such as the gastrointestinal tract that play an important role in the metabolism of steroid hormones and fatty acids. 1 Its name was derived from its spectral absorbance maximally produced near 450 nm when carbon mon- oxide binds to the enzyme at its reduced state. CYP450 also plays a part in the metabolism of various drugs and exogenous chemicals. 1 Within the P450 superfam- ily, families are designated by Arabic numeral (eg, CYP3). Members of the same family have to have more than 40% identical amino acid sequence. 2 If the amino acid sequence is more than 55% identical, they will be categorized as a subfamily (eg, CYP3A). An Arabic numeral is added to the subfamily to identify each individual enzyme (eg, CYP3A4). If the designation is printed in italics, it represents the gene associated with the enzyme (eg, CYP3A4). CYP1, CYP2, and CYP3 are the three families responsible for most drug and carcinogen metabolism. 1 The CYP1 family may also play a role in carcinogenic activation, 1 whereas CYP2 and CYP3 are characterized by their inducibility by different medications such as phenobarbital 3,4 and their ability to metabolize a wide variety of drugs (Table 1). 1,5 Drugs that are metabolized by the same CYP450 enzyme family, when administered concurrently, may interact and affect systemic clearance of each other. The nature, extent, and clinical signicance of these inter- actions also depend on whether the interacting agents are substrates, inducers, or inhibitors of the CYP450 enzyme. Genetic polymorphism in the functional expression of some CYP450 enzymes, such as CYP2D6, also plays a signicant role in determining interpatient variability in the degree of drug metabolism. Other factors such as age, nutrition, stress, hepatic disease, hormones, and other endogenous chemicals also play a role in determining the signicance of the drug interaction. SUBSTRATES, INHIBITORS, AND INDUCERS A CYP450 substrate is an exogenous or endogenous substance metabolized by CYP450. Some drugs may 1 Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, NY and the Mt. Sinai Medical Center, New York, NY; and 2 Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY. *Address for correspondence: Cardiology Division, New York Medical College, Macy Pavilion, Room 138, Valhalla, NY 10595. E-mail: WSAronow@aol.com American Journal of Therapeutics 00, 000000 (2009) 10752765 2009 Lippincott Williams & Wilkins be metabolized by more than one CYP450 enzyme and are considered substrates for multiple enzymes. For example, tricyclic antidepressants are metabolized by CYP2D6, CYP1A2, and CYP3A4. 5 In this situation, when one of the enzymes is inhibited by another agent, a clinically signicant interaction may be less likely to occur because of shared metabolism among enzymes. A CYP450 inhibitor is an exogenous or endogenous substance that will inhibit the activity of the CYP450 enzymes but may not necessarily be metabolized by the enzymes themselves (eg, cimetidine). Inhibition occurs as a result of competitive binding at the en- zymes binding site, which prevents the enzyme from metabolizing other agents. The onset and offset of enzyme inhibition by an individual inhibitor are dependent on the half-life of the inhibitor. For example, cimetidine ( with a half-life of approximately 2 hours and inhibits CYP1A2) inhibits drug metabolism by CYP1A2 within 24 hours of a single dose administration. But its inhibitory effect will also disappear within 24 hours of drug discontinuation. On the other hand, amiodarones (with a half-life of 30 to 60 days and inhibits CYP2C9) inhibitory action may not take place for months because of its long half-life, and its inhibitory effect will also last for months after drug discontinuation. 6 Likewise, a CYP450 inducer is an agent that will increase the activity of CYP450 enzymes but also may not necessarily be metabolized by the enzymes themselves (eg, phenobarbital). Similarly to inhibitors, the onset of enzyme induction is dependent on the half-life of the inducer agent. In addition, the time course of induction is also dependent on the time required for new enzyme production as well as a patients age and liver function. Table 2 lists some Table 1. Major drugs metabolized by cytochrome P450 enzymes. 1,51,5 CYP450 enzymes Substrate* CYP1A2 Amitriptyline, caffeine, clomipramine, clozapine, cyclobenzaprine, desipramine, diazepam, estradiol, uvoxamine, haloperidol, imipramine, mexiletine, naproxen, olanzapine, ondansetron, acetaminophen, propranolol, theophylline, verapamil, warfarin, zileuton, zolmitriptan CYP2B6 Bupropion, cyclophosphamide, efavirenz, ifosfamide, methadone CYP2C8 Paclitaxel, torsemide, repaglinide CYP2C9 Nonsteroidal anti-inammatory agents (diclofenac, ibuprofen, meloxicam, naproxen, piroxicam), sulfonylurea (tolbutamide, gluburide, glipizide, glimerpiride, netaglinide), angiotensin II blockers (losartan, irbesartan), amitriptyline, celecoxb, uoxetine, uvastatin, phenytoin, rosiglitazone, tamoxifen, torsemide, warfarin. CYP2C18 Omeprazole, proguanil, propranolol, retinoic acid , S-mephenytoin, S-tetrahydrocannabinol CYP2C19 Proton pump inhibitors (lansoprazole, omeprazole, pantoprazole, rabeprazole), anti-epileptics (diazepam, phenytoin, phenobarbital), amitriptyline, citalopram, clomipramine, cyclophosphamide, imipramine, indomethacin, nelnavir, primidone, progesterone, proguanil, propranolol, warfarin CYP2D6 Antiarrhythmic agents (ecainide, mexiletine, propafenone), antipsychotics (chlorpromazine, clozapine, haloperidol, resperidone), b-blockers, Fluoxetine, paroxetine, venlafaxine, metoclopramide, monoamine oxidase inhibitors, narcotics (codeine, hydrocodone, meperidine, methadone, morphine), ondesantron, tramadol, tricyclic antidepressants CYP2E1 Anesthetics (eurane, halothane, isourane), acetaminophen, alcohol, theophylline CYP3A3 Benzphetamine, erythromycin, cyclosporin, vinca alkaloids CYP3A4, 5, 7 Clopidogrel (not 3A5, 3A7), macrolide antibiotics (clarithromycin, erythromycin (not 3A5), telithromycin), antiarrhythmics (quinidine (not 3A5), amiodarone), benzodiazepines (alprazolam, diazepam, midazolam, triazolam), immune modulators (cyclosporine, tacrolimus), antiretrovirals (indinavir, nelnavir, ritonavir, saquinavir), calcium channel blockers (amlodipine, diltiazem, felodipine, nifedipine, nisoldipine, nitrendipine, verapamil) HMGCoA reductase inhibitors (atorvastatin, lovastatin, simvastatin), steroids (dexamethasone, estradiol, hydrocortisone, progesterone, testosterone), antipsychotics (aripiprazole, haloperidol, quetiapine, risperidol, ziprasodone), tricyclic antidepressants, cilostazol, cocaine, caffeine, codeine, dapsone, dextromethorphan, eplerenone, fentanyl, methadone, natglinide, ondansetron, propranolol, salmeterol, sildenal, sirolimus, tamoxifen, trazadone, buspirone, zolpidem, zaleplon CYP4A11 Leukotriene receptor antagonists *Drugs in bold are cardiovascular agents. American Journal of Therapeutics (2009) 00(0) 2 Cheng et al major inhibitors and inducers of different CYP450 enzymes. 1,5 CLINICALLY SIGNIFICANT CYP450 CARDIOVASCULAR DRUG INTERACTIONS Angiotensin II receptor antagonists Two of the angiotensin II receptor antagonists currently available on the market (losartan, irbesartan) are metabolized by CYP2C9 (primarily) and CYP3A4 (to a minor extent). Although no signicant clinical drug interactions have been reported to date, signicant inhibition of these two enzymes by other agents can potentially inhibit their metabolism, and therefore careful monitoring of toxicity is required. It has been reported that rifampin, by inducing CYP2C9 and CYP3A4 activities, decreases the half-life of losartan and its metabolite by 50% in healthy volunteers. 7 It has also been demonstrated that when uconazole, a potent CYP2C9 inhibitor, was administered daily for 20 days to 16 male subjects who received daily doses of losartan, it signicantly raised plasma concentrations of losartan and inhibited formation of the active metabolite. 8 These changes in plasma concentrations of the active drugs and metabolites, however, did not produce signicant changes in clinical response such as reduction in blood pressure. Antiarrhythmic drugs Quinidine is itself metabolized by the CYP3A4 enzyme but inhibits CYP 2D6. CYP3A4 interactions with quinidine that are well documented include those with cimetidine, phenytoin, phenobarbital, and rifampin. 912 Signicant interaction has also been reported between quinidine and erythromycin. 13 Erythromycin has been reported to increase quinidine concentrations by 142%. Quinidine concentrations should be monitored and patients assessed for signs of toxicity in these situations. Amiodarone is also metabolized by the CYP3A4 enzymes. Phenytoin, by inducing CYP3A4, has been reported to enhance amiodarone metabolism and decrease plasma concentrations by as much as 49%. 14 On the other hand, amiodarone inhibits CYP2C9, thus inhibiting phenytoin metabolism, resulting in doubling plasma phenytoin levels. 15 When amiodarone is ad- ministered concurrently with warfarin therapy, pro- thrombin time may double in 3 to 4 days. 16 This is because warfarin is partially metabolized by CYP2C9, as with phenytoin. Similarly, quinidine also interacts with amiodarone, resulting in signicantly prolonged Table 2. Major inhibitors and substrates of different CYP450 enzymes. 1,5 CYP450 enzymes Inhibitors* Inducers* CYP1A2 Amiodarone, cimetidine, ciprooxacin, clarithramycin, erytrhomycin, oroquinolones, uvoxamine Insulin, omeprazole, phenobarbital, phenytoin, rifampin, smoking CYP2B6 Ticlopidine Phenobarbital, rifampin CYP2C8 Trimethoprim, glitazones, gembrozil, montelukast Rifampin CYP2C9 Amiodarone, fenobrate, uconazole, uvastatin, uvozamine, isoniazid, lovastatin, phenybutazone, probenecid, seatrain, sulfamethoxazole, variconazole Carbamazepine, phenobarbital, phenytoin, rifampin CYP2C19 Chloramphenicol, cimetidine, uoxetine, uvoxamine, indomethacin, ketoconazole, lansoprazole, omeprazole, oxcarbamazepine, probenecid, ticlopidine, topiramate Carbamazepine, prednisone, rifampin CYP2D6 Amiodarone, buproprion, celecoxib, cimetidine, chlorpromazine, chlopheniramine, citalopram, cocaine, desipramine, diphenhydramine, doxepin, doxorubicin, escitalopram, uoxetin, uphenazine, haloperidol, metoclopramide, methadone, midodrine, paroxetin, propafenone, quinidine, ranitidine, ritonavir, sertraline, ticlopidine Carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, ritonovir CYP3A4, 5, 7 Amiodarone, cimetidine, clarithromycin, erythromycin, delaviridine, diltiazem, uconazole, uoxetin, uvoxamine, grapefruit juice, indinavir, itraconazole, ketoconazole, metronidazole, nefazodone, nelnavir, ritonavir, saquinavir, verapamil, voriconazole, zarlukast Carbamazepine, corticosteroids, ethosuximide, phenobarbital, phenytoin, rifabutin, rifampin, glitazone *Drugs in bold are cardiovascular agents. American Journal of Therapeutics (2009) 00(0) CYP450 Cardiovascular Drug Interactions 3 QT intervals. Quinidine clearance is reduced by amiodarone, and plasma concentrations of quinidine may increase by 32%when administered concurrently. 17 In addition, amiodarone may increase plasma concen- trations of hepatically metabolized beta-blockers and calcium channel blockers. When the agents are admin- istered concomitantly, decreasing the doses of each agent may be necessary. Antidepressants such as uvoxamine, uoxetine, sertraline, and nefazodone have high CYP450 inhibitory potential and may decrease amiodarone metabolism, thus increasing amiodarone plasma concentrations. 18 Antiplatelet drugs Clopidogrel is a prodrug that requires in vivo conversion by CYP3A4 to an active metabolite (an unstable thiol compound) to exert its antiplatelet effect. 1921 Because of this, if clopidogrel is adminis- tered with CYP3A4 inhibitors, the amount of active metabolite produced may be decreased, thus dimin- ishing its antiplatelet effect. In a study evaluating the loading dose of clopidogrel in inhibiting platelet aggregation after coronary artery angioplasty, it was observed that the effectiveness of clopidogrel was diminished in patients who were taking atorvastatin. 22 The average platelet aggregation of patients receiving clopidogrel alone was 42% compared with those who received clopidogrel and atorvastatin (68%, P = 0.03). Another study evaluated the ability of clopi- dogrel in inhibiting platelet aggregation in patients taking either atorvastatin, a CYP3A4 inhibitor, or pravastatin, a non-CYP3A4 inhibitor. 23 Forty-four patients undergoing coronary artery stent implanta- tion treated with clopidogrel demonstrated that the degree of platelet aggregation inhibition achieved 24 hours after clopidogrel administration was signif- icantly attenuated by atorvastatin as compared with the controls (77% aggregation with atorvastatin vs. 34%aggregation with placebo; P ,0.0001). In contrast, clopidogrel inhibited platelet aggregation in both the control group and patients taking pravastatin (34% aggregation and 46% aggregation, respectively; P = NS). Cilostazil is a phosphodiesterase inhibitor III in- dicated for management of intermittent claudication in patients with peripheral arterial disease through its antiplatelet activity. Cilostazil is metabolized by CYP 1A2, 2D6, 3A, and 2C19. Its drug interaction prole has not been fully elucidated. A study demonstrated that after erythromycin coadministration, cilostazol maxi- mum plasma concentration increased signicantly by 47%. The clinical signicance of such an interaction, however, is unknown. 24 Beta-adrenergic blockers Pharmacokinetic proles of many lipophilic beta- adrenergic blockers such as propranolol are strongly affected by CY P450 inducers and inhibitors. 25 For example, rifampin causes a two- to threefold increase in propranolol clearance, which lowers plasma propran- olol concentrations to subtherapeutic levels. 26 Quini- dine inhibits CYP2D6 activity, thus inhibiting hepatic metabolism of propranolol and raising its plasma concentrations. 26 Other clinically relevant drug inter- actions involving beta-blockers include cimetidine, which leads to additional reduction in heart rate and intraocular pressure when administered together with timolol ophthalmic solution by inhibiting CYP2D6. 27,28 Calcium channel blockers Most calcium channel blockers are metabolized exten- sively by CYP450 enzymes. When concurrent therapies of potent CYP450 inhibitors are required, the patient should be monitored for signs of toxicity (hypotension, bradycardia, or tachycardia) and the dosage of calcium channel blocker decreased, if necessary. On the other hand, when potent CYP450 inducers are administered concurrently with calciumchannel blockers, the dosage may have to be increased to achieve optimal thera- peutic effects. Clinically signicant drug interactions caused by enzyme inhibition reported for calcium channel block- ers include that occurring with grapefruit juice, a potent CYP3A4 inhibitor. Grapefruit juice, 200 to 250 mL, when administered with felodipine, increased the area under the concentration time curve of felodipine by 185%. Similar results were demonstrated with nifed- ipine and verapamil but not with diltiazem. 29,30 Signicant drug interactions were also reported when felodipine (10 mg/day) was administered with oral erythromycin 250 mg twice daily. Patients developed ushing, ankle and leg edema, as well as tachycardia. 31 Other reports also documented substantial peripheral edema or elevated felodipine serum concentrations when administered concurrently with itraconazole 200 mg daily. This was also associated with statistically signicant changes in systolic and diastolic blood pressures and heart rate. 32 Daily doses of cimetidine (8001200 mg) signicantly increased the mean total area under the plasma nifedipine concentration time curve. Corresponding to this increase in the bio- availability of nifedipine caused by cimetidine, longer duration of changes in heart rate were observed in patients in the standing position. 33,34 These ndings indicate that doses of nifedipine should be reduced by 50% when the drug is coadministered with cimetidine. American Journal of Therapeutics (2009) 00(0) 4 Cheng et al Signicant drug interactions with calcium channel blockers caused by enzyme induction by other agents include that with rifampin. Rifampin has been demon- strated to increase verapamil clearance by 32-fold. 35 Calcium channel blockers inhibit the metabolism of cyclosporine. 36 Diltiazem in doses as low as 10 mg increased the bioavailability of cyclosporine and resulted in the need for a lower dose to maintain efcacy or avoid toxic effects. 37 Because cyclosporine is an expensive drug, the coprescribing of diltiazem and cyclosporine is a way of reducing the high costs of cyclosporine. 38 Similarly, the verapamil-induced change in cyclosporine pharmacokinetics allows the dose of cyclosporine to be reduced by one third to one half. 39 Verapamil signicantly increased mean peak serum concentration and bioavailability of simvastatin. 40 This interaction probably results from the inhibition of CYP3A4 or P-glycoprotein by verapamil. Although the clinical signicance of this nding is not clear, the manufacturer of simvastatin recommends to avoid concurrent use of simvastatin and verapamil, and if the two agents must be used together, the dose of simvastatin be kept at a maximum of 20 mg. 41 One meta-analysis suggested that, overall, calcium channel blockers do not increase the risk of myopathy when used concomitantly with simvastatin. 42 Diltiazem inhibits the metabolism of triazolam, probably by inhibiting the activity of CYP3A. 43 When patients using diltiazem were anesthetized with large doses of midazolam, a signicant delay in tracheal extubation was attributed to reduced metabolism of these anesthetics secondary to inhibition of CYP3A by diltiazem. 44 Similarly, diltiazem increased plasma levels of methylprednisolone, which enhanced sup- pression of morning plasma cortisol levels. This nding suggests that care should be taken when methylpred- nisolone is coadministered with diltiazem for a pro- longed period of time. 45 Diuretics Torsemide and eplerenone are two diuretics that are metabolized by the CYP450 system (CPY2C4 and CYP3A4, respectively). A clinically signicant drug interaction of torsemide involving the CYP450 system has not been reported. Eplerenone is metabolized primarily by CYP3A4. A potent inhibitor of CYP3A4 such as ketoconazole increased serum concentra- tion of eplerenone by vefold, whereas less potent CYP3A4 inhibitors such as erythromycin and vera- pamil increased serum concentration of eplerenone by threefold. The administration of grapefruit juice with eplerenone was reported to increase serum eplerenone concentration by 25%. 46 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors Three of the six 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors marketed in the United States are metabolized primarily by CYP3A4 (atorvastatin, lovastatin, simvastatin). Dose-related toxic effects on skeletal muscle are well documented with HMG-CoA reductase inhibitors. 47 Risk of de- veloping rhabdomyolysis increases as this class of drug is used in combination with other CYP3A4 inhibitor agents that compete with CYP3A4 metabolism (eg, cyclosporin, gembrozil, niacin, erythromycin). 48,49 As mentioned in the previous section on calcium channel blockers, the manufacturer of simvastatin has made several recommendations of daily maximum doses of simvastatin use when it is administered concurrently with several CYP3A4 inhibitors. 41 When administered concurrently with verapamil or amiodarone, the max- imum dosage of simvastatin used should not exceed 20 mg per day to minimize the risk of myopathy. When administered with cyclosporin, danazol, and gem- brozil, the maximum daily dose of simvastatin usage should not exceed 10 mg. Bleeding or prolonged prothrombin time was reported in several patients taking HMG-CoA reduc- tase inhibitor (those metabolized by CYP3A4) concomi- tantly with warfarin. 50 Fluvastatin and pravastatin, on the other hand, have not been reported to interact with warfarin. Warfarin Warfarin has an extensive drug interaction prole. R-warfarin is a substrate of CYP3A4. Therefore, any medications that are inducers or inhibitors of CYP3A4 will interact with R-warfarin pharmacokinetically. Fluconazole, itraconazole, and ketoconazole have been reported to increase the anticoagulant effects of warfarin by two- to three fold. 5153 Numerous reports describe the enhancement of the hypoprothrombine- mic effects (up to 2-fold) of warfarin when given in combination with erythromycin and clarithromy- cin. 54,55 Azithromycin has not been reported to have such an interaction. The clinical relevance of any warfarin interactions depends on many other patient factors including age, rates of warfarin clearance, and other concurrent drug therapy. Omeprazole, a proton pump inhibitor, inhibits the metabolism of R-warfarin through inhibition of CY- P3A4 enzyme. The effects appear after omeprazole has been administered for a few days, and it appears to be dose related. This effect does not abate until several days after discontinuation of omeprazole. 56 Careful drug monitoring is therefore required. American Journal of Therapeutics (2009) 00(0) CYP450 Cardiovascular Drug Interactions 5 CLINICALLY SIGNIFICANT CYP450 NONCARDIOVASCULAR DRUG INTERACTIONS THAT PRODUCE CARDIOVASCULAR SIDE EFFECTS Antidepressants and antipsychotics Certain selective serotonin reuptake inhibitors (SSRI) are substrates of CYP450 enzymes and potent inhib- itors of CYP2D6 (eg, uoxetine, nefazadone, parox- etine, sertraline). Antipsychotics, especially the newer generation atypical antipsychotics, are substrates of CYP450 enzymes but neither inhibit nor induce the CYP450 enzymes. Coadministration of SSRI with tricyclic antidepressants and antiarrhythmics have been reported to increase the risk of developing Torsades de Pointes. 57,58 Several studies have docu- mented that uvoxamine, a new SSRI, may elevate plasma levels of olanzapine by approximately two times, presumably through inhibition of CYP1A2, with possible occurrence of unwanted effects. In particular, in eight patients stabilized on olanzapine therapy (1020 mg/day), the addition of uvoxamine (100 mg/day) for 8 weeks increased plasma olanzapine levels by approximately 80%, which increased the incidence of sedation, orthostatic hypotension, tachy- cardia, and elevation of transaminase. 59 Antihistamines Both terfenidine and aztemizole are two rst-generation nonsedating antihistamines that have been removed fromthe market because of their serious cardiovascular drug interaction. Terfenidine and aztemizole are substrates of CYP3A4. Terfenidine was rst reported to cause QT interval prolongation and Torsades de Pointes when coadministered with ketoconazole in 1990. 60 A prospective study of six healthy volunteers given the combination were noted to have increased terfenidine plasma concentrations and QT prolon- gation. 61 Such interaction is observed because of ketoconazoles inhibitory activity on CYP3A4 enzyme, which is responsible for metabolizing terfenidine. This leads to increased serum concentration of the parent compound, terfenidine, which is arrhythmogenic. Other antifungal agents such as itraconazole and uconazole have less inhibitory effect on CYP3A4. 62 Therefore, in dosages used clinically, the incidence of arrhythmia is low. 63 Astemizole undergoes extensive rst-pass metabolism to form active metabolites, and similar to terfenidine, the parent compound is also the cardiotoxic entity. Therefore, in many circumstances, drug interactions of terfenidine have been extrapolated to astemizole. 64 Erythromycin is another inhibitor of CYP3A4 enzyme and in itself can also cause QT prolongation. 64 Therefore, when coadministered with terfenidine or aztemizole, it may increase the risk of arrhythmia. 65 This effect was also reported with clarithromycin but not with azithromycin. 66 Because the accumulations of terfenadine and aztemizole can lead to prolongation of QT intervals and devastating arrhythmias, coadministration of these antihistamines with other agents that are also capable of prolonging QT will, through a pharmacodynamic interaction, increase the risk of developing Torsades de Pointes. Agents that are known to prolong QTintervals are listed in Table 3. 67 Antimicrobials and antifungals Macrolides (except azithromycin) are substrates and inhibitors of CYP3A4. Coadministration of CYP3A inhibitors (antifungal agents, diltiazem, verapamil, and troleandomycin) with erythromycin has been associ- ated with a doubling of the risk of sudden cardiac death caused by increased concentrations of erythromycin. 68 Ketoconazole, itraconazole, uconazole, and vorico- nazole have been shown to prolong the QT interval and to be associated with Torsades, with the majority of reports of Torsades stemming from CYP450 involving drug interactions and relating to ketoconazole and itraconazole. 6973 In addition, allelic polymorphisms of CYP2C19 have demonstrated the greatest impact on voriconazole clearance, resulting in either poor or extensive metabolism of this drug and leading some to suggest the need for therapeutic drug monitoring. 74 To date, no postmarketing database evaluations charac- terizing azole-associated Torsades have been published. Cisapride Cisapride was rst observed in a review of records of more than 13,000 patients to cause tachycardia, Table 3. Pharmacologic agents capable of prolonging QT intervals. 41 Antiarrhythmics Antipsychotics Chloroquin Cisapride Droperidol Tricyclic antidepressants Fluconazole Itraconazole Ketoconazole Macrolides (erythromycin, clarithomycin) Methadone Pentamadine American Journal of Therapeutics (2009) 00(0) 6 Cheng et al palpitations, and extrasystoles. 75 Postulations of the cause of tachycardia include activation of serotonin-4 receptors on the myocardium and prolonged atrioven- tricular conduction because of its structural similarity to procainamide. The rst report of arrhythmia drug interaction was reported between cisapride and eryth- romycin. The patient developed prolonged QT interval with progression to Torsades. 76 Since then, Janssen Pharmaceutical, who markets cisapride, continues to receive numerous reports of Torsades. More than 50% of these patients were concomitantly receiving other medications that may prolong QT intervals. 77 The mechanism of these interactions is believed to be competitive binding and inhibition of CYP3A4 enzyme by cisapride. In 2000, Janssen Pharmaceutical decided to stop marketing Cisapride in the United States but continued to make the drug available to those patients whom their physicians still considered to receive benets from cisapride that outweighed its risks. 78 Grapefruit juice Grapefruit juice is a potent inhibitor of gut wall CYP3A4, which is important in metabolism of all dihydropyridines, HMG-CoA reductase inhibitors, cisapride, midazolam, and cyclosporin. It is now known that grapefruit juice on average increases felodipine area under the curve by 240% and increases nisoldipine peak plasma concentration by vefold. 79,80 In addition to CYP3A4, grapefruit juice has also demonstrated to signicantly inhibit CYP1A2. 80 This will be of particular importance in patients taking propafenone and warfarin. Methadone Recent studies and case series have associated the use of methadone with development of prolonged QT intervals and Torsades. 81 Methadone is metabolized by CYP3A4 and to a lesser extent CYP2D6. Therefore, coadministration of methadone with agents that inhibit CYP3A4 and CYP2D6 may increase the risk of Torsades. In a case control study examining 40 patients with reported methadone-induced Torsades de Pointes, the concurrent use of agents that inhibit CYP3A4 increase the risk of Torsades by 55%. 82 In one case series, therapy with nelnavir, a potent inhibitor of CYP3A4, when administered with meth- adone, caused torsade de pointes. 83 CONCLUSION Numerous cardiovascular agents are substrates, inhib- itors, or inducers of CYP450 enzymes. 84 The improved understanding of the CYP450 system, their substrates, inhibitors, and inducers allow us to predict potential drug interactions. This review discusses the general principles of occurrence of these interactions with selected published signicant examples. Continued in vivo drug interaction studies and reporting by clini- cians are necessary to establish the clinical signicance of these interactions and will help to prevent and manage these drug interactions. REFERENCES 1. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmac Ther. 1990;45:138. 2. Slaughter RL, Edwards DJ. Recent advances: the cyto- chrome P450 enzymes. Ann Pharmacother. 1995;29: 619624. 3. Guengerich FP, Dannan GA, Wright ST, et al. Purication and characterization of liver microsomal cytochrome P450: electrophoretic, spectral, catalytic and immuno- chemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or B-naphthoavone. Biochemistry. 1982;21:60196030. 4. Waxman DJ, Walsh C. Phenobarbital-induced rat liver cytochrome P-450-purication and characterization of two closely related isozymic forms. J Biol Chem. 1982;2257: 1044610457. 5. P450 tables. Available at: http://medicine.iupui.edu/ ockhart/table.htm Accessed March 25, 2007. 6. Heimark LD, Wienkers L, Dunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51:398407. 7. Williamson KM, Patterson JH, McQueen RH, et al. Effects of erythromycin or rifampin on losartan pharmacokinet- ics in healthy volunteers. Clin Pharmacol Ther. 1998;63: 316323. 8. Kazierad DJ, Martin DE, Blum RA, et al. Effect of uconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther. 1997;62:417425. 9. Slaughter RL, Edwards DJ. Recent advances: the cyto- chrome P450 enzymes. Ann Pharmacother. 1995;29:619624. 10. Shinn AF. Clinical relevance of cimetidine drug inter- actions. Drug Saf. 1992;7;24567. 11. Levy RH. Cytochrome P450 isoenzyme and antiepileptic drug interactions. Epilepsia. 1995;36(Suppl 5):S8S13. 12. Venkatesan K. Pharmacokinetic drug interactions with rifampin. Clin Pharmacokinet. 1992;22:4765. 13. Spinler S, Cheng JWM, Kindwall KE, et al. Possible inhibition of hepatic metabolism of quinidine by eryth- romycin. Clin Pharmacol Ther. 1995;57:8994. 14. Nolan PE Jr, Marcus FL, Karol MD, et al. Effect of phenytoin on the clinical pharmacokinetics of amiodar- one. J Clin Pharmacol. 1990;30:11121119. 15. Gore JM, Haffajee CI, Alpert JS. Interaction of amiodarone and diphenylhydantoin. Am J Cardiol. 1984;54:1145. 16. Marcus FI. Drug interactions with amiodarone. Am Heart J. 1983;106:924930. American Journal of Therapeutics (2009) 00(0) CYP450 Cardiovascular Drug Interactions 7 17. Saal AK, Werner JA, Greene HL, et al. Effect of amiodarone on serumquinidine and procainamide levels. Am J Cardiol. 1984;53:12641267. 18. DeVane CL, Gill HS, Markowitz JS, et al. Awareness of potential drug interactions may aid avoidance. Ther Drug Monit. 1997;19:366367. 19. Savi P, Pereillo JM, Uzabiaga MF, et al. Identication and biological activity of the active metabolite of clopidogrel. Throm. Haemost. 2000;84:891896. 20. Hasegawa M, Sugidachi A, Ogawa T, et al. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005;94: 593598. 21. Kazui M, Ishizuka T, Yamamura N, et al. Mechanism of production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist. Thromb Haemost. 2001;12(Suppl):P1916. 22. Lau C, L. Waskell LA, Carville D, et al. The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation. 2000;102:2086. 23. Lau C, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drugdrug interaction. Circulation. 2003;107:3237. 24. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazil. Clin Pharma- cokinet. 1999;37(Suppl 2):6168. 25. Wood AJ. Drug interactions in hypertension. Hyperten- sion. 1988;11:II-1II-3. 26. Herman RJ, Nakamura K, Wilkinson GR, et al. Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol. 1983;16:565569. 27. Ishii Y, Nakamura K, Tsutsumi K, et al. Drug inter- action between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol. 2000;40: 193199. 28. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA. 1995;274:16111613. 29. Fuhr U, Dummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions. Clin Pharmacol Ther. 1995;58:364373. 30. Abramowicz M, ed. Grapefruit juice interactions with drugs. Med Lett. 1995;37:6364. 31. Nordine LH. Erythromycin-felodipine interaction [Let- ter]. Drug Intell Clin Pharm. 1991;25:10071008. 32. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther. 1997;61:410415. 33. Smith SR, Kendall MJ, Lobo J, et al. Ranitidine and cimetidine drug interactions with single dose and steady- state nifedipine administration. Br J Clin Pharmacol. 1987; 23:311315. 34. Schwartz JB, Upton RA, Lin ET, et al. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988;43: 673680. 35. Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996;24:796801. 36. Chiu SH. The use of in vitro metabolism studies in the understanding of new drugs. J Pharmacol Toxicol Methods. 1993;29:7783. 37. Jones DR, Gorski JC, Hamman MA, et al. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther. 1999;290:11161125. 38. Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. Br J Clin Pharmacol. 1997;44:499504. 39. Campana C, Regazzi MB, Buggia I, et al. Clinically signicant drug interactions with cyclosporin: an update. Clin Pharmacokinet. 1996;30:141179. 40. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64:177182. 41. Zocor prescribing information. Available at: http:// www.zocor.com/zocor/shared/documents/english/pi.pdf. Accessed April 24, 2007. 42. Gruer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999;84:811815. 43. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther. 1996;59:369375. 44. Ahonen J, Olkkola KT, Salmenpera M, et al. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology. 1996;85:12461252. 45. Varis T, Backman JT, Kivisto KT, et al. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methyl- prednisolone. Clin Pharmacol Ther. 2000;67:215221. 46. Cook CS, Berry LM. Burton E. Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica. 2004;34:215228. 47. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. 1. Efcacy in modifying plasma lipoproteins and adverse event prole in modifying plasma lipoproteins and adverse event prole in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:4349. 48. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366385. 49. Ayanian JZ, Ruchs CS, Stone RM. Lovastatin and rhabdomyolysis [Letter]. Ann Intern Med. 1988;109: 682683. 50. Garnett WR. Interactions with hydroxymethylglutaryl- coenzyme A reductase inhibitor. Am J Health Syst Pharm. 1995;52:16391645. American Journal of Therapeutics (2009) 00(0) 8 Cheng et al 51. Kunze KL, Wienkers LC, Thummel KE, et al. Warfarin-uconazole. 1. Inhibition of human cytochrome P450-dependent metabolism of warfarin by uconazole: in vitro studies. Drug Metab Dispos. 1996;24:422428. 52. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin- uconazole. II. A metabolically based drug interaction: in vitro studies. Drug Metab Dispos. 1996;24:422428. 53. Gillum JG, Isreal DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet. 1993;25:450482. 54. Oberg KC. Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. Pharmacotherapy. 1998;18:386391. 55. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterolog.y 1985;89:12351241. 56. Nemeroff CB, DeVane L, Pollock BG. Newer antidepres- sants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311320. 57. Brosen K. Are pharmacokinetic drug interactions with SSRIs an issue? Int Clin Psychopharmaco.l 1996;11(Suppl 1): 2327. 58. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenidine use. JAMA. 1990;264:27882790. 59. Hiemke C, Avi P, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol. 2002;22:502506. 60. Honig PK, Woosley RL, Zamani K, et al. Terfenadine- ketoconazole interaction pharmacokinetic and electrocar- diographic consequences. JAMA. 1993;269:15131518. 61. Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenidine metabolism: pharmacokinetic and pharmaco- dynamic consequences. Clin Pharmacokinet. 1994;7:15. 62. Gillum JG, Isreal DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet. 1993;25:450482. 63. Oberg K, Bauman JL. QT interval prolongation and Torsades de pointes due to erythromycin lactobionate. Pharmacotherapy. 1995;15:687692. 64. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacody- namics of terfenidine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;52:213218. 65. Amsden GW. Macrolides versus azalides: a drug inter- action update. Ann Pharmacother. 1995;29:906917. 66. Inman W, Kubota K. Tachycardia during cisapride treatment. BMJ. 1992;305:748749. 67. Arizona Center for Education and Research on Thera- peutics. Drugs with risk of Torsades de Pointes. Available at: http://www.arizonacert.org/medical-pros/drug-lists/ drug-lists.htm. Accessed March 25, 2007. 68. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death fromcardiac causes. N Engl J Med. 2004;351:10891096. 69. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of uconazole and amitriptyline. Am J Emerg Med. 2000;18:227229. 70. Hoover CA, Carmichael JK, Nolan PE Jr, et al. Cardiac arrest associated with combination cisapride and itraco- nazole therapy. J Cardiovasc Pharmacol Ther. 1996;1:255258. 71. Khazan M, Mathis AS. Probable case of torsades de pointes induced by uconazole. Pharmacotherapy. 2002;22: 16321637. 72. Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachy- cardia. Eur J Clin Pharmacol. 1993;45:191193. 73. Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketocona- zole. Eur Heart J. 1992;13:10021003. 74. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemo- ther. 2006;50:15701572. 75. Bran S, Murray W, Hirsch IB, et al. Long QT syndrome during high dose cisapride. Arch Intern Med. 1995;155: 765768. 76. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhyth- mia. N Engl J Med. 1996;335:290291. 77. Zechnich AD, Hedges JR, Eiselt-Proteau D, et al. Possible interactions with terfenidine or astemizole. West J Med. 1994;160:321325. 78. Janssen Pharmaceutica stops marking Cisapride in the US. Available at: http://www.fda.gov/bbs/topics/ ANSWERS/ANS01007.html. Accessed March 29, 2007. 79. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol. 1996;16:101103. 80. Merkel U, Sigusch H, Hoffman A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volun- teers. Eur J Clin Pharmacol. 1994;46:175177. 81 Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747753. 82. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very high dose methadone. Ann Intern Med. 2002;137:501504. 83. Justo D, Gal-Oz A, Paran Y, et al. Methadone associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101:1333 1338. 84. Opie LH. Cardiovascular drug interactions. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, ed 2. New York: McGraw Hill, 2003: 875891. American Journal of Therapeutics (2009) 00(0) CYP450 Cardiovascular Drug Interactions 9